WO2006094451A1 - Utilisation d’acide chlorhydrique pour la fabrication d’un medicament pour le traitement de l'hypertension - Google Patents

Utilisation d’acide chlorhydrique pour la fabrication d’un medicament pour le traitement de l'hypertension Download PDF

Info

Publication number
WO2006094451A1
WO2006094451A1 PCT/CN2006/000329 CN2006000329W WO2006094451A1 WO 2006094451 A1 WO2006094451 A1 WO 2006094451A1 CN 2006000329 W CN2006000329 W CN 2006000329W WO 2006094451 A1 WO2006094451 A1 WO 2006094451A1
Authority
WO
WIPO (PCT)
Prior art keywords
hydrochloric acid
aqueous solution
hypertension
medicament
preparation
Prior art date
Application number
PCT/CN2006/000329
Other languages
English (en)
French (fr)
Inventor
Zhiren Liu
Original Assignee
Zhiren Liu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhiren Liu filed Critical Zhiren Liu
Priority to EA200701936A priority Critical patent/EA012616B1/ru
Priority to MX2007010918A priority patent/MX2007010918A/es
Priority to AU2006222417A priority patent/AU2006222417A1/en
Priority to US11/908,053 priority patent/US20080317871A1/en
Priority to JP2008500030A priority patent/JP2008532952A/ja
Priority to EP06705725A priority patent/EP1864671A4/en
Priority to BRPI0608022-7A priority patent/BRPI0608022A2/pt
Publication of WO2006094451A1 publication Critical patent/WO2006094451A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Definitions

  • the present invention relates to the use of hydrochloric acid in the preparation of a medicament for the treatment of diseases such as hypertension and stones.
  • the object of the present invention is to provide an application of hydrochloric acid in the preparation of a medicament for treating hypertension.
  • the formation of hypertension is based on the following mechanisms: 1. Binder calcium carbonate and calcium oxalate formed by decomposition of calcium bicarbonate in water and food to metabolize human body (such as cholesterol) Crystallization, etc., and the solid matter entering the human body adhere to the inner wall of the arterial blood vessel and the capillary. As the age increases, the scale on the inner wall of the arterial blood vessel and the capillary becomes thicker and thicker, and the pore diameter of the blood vessel becomes smaller and smaller, thereby making Poor blood flow, increased blood pressure;
  • these calcium carbonate and calcium oxalate are deposited in organs such as kidney, liver and gallbladder, and kidney stones, liver stones and gallstones are formed.
  • hydrochloric acid is the most ideal substance for dissolving ⁇ ⁇ and calcium oxalate in human body.
  • hydrochloric acid is adsorbed on the inner wall by a protective membrane of blood vessels, which can repair damaged blood vessels and restore the blood vessels to their own elasticity.
  • hydrochloric acid helps dissolve kidney stones, liver stones and gallstones, thereby relieving or eliminating stones. Therefore, in a first aspect of the invention, there is provided a use of hydrochloric acid for the preparation of a medicament for the treatment of hypertension.
  • the pH of the aqueous solution is controlled to be 3-6.9 (more preferably 4-6. 5).
  • the pH of the aqueous solution is controlled at 6. 5 ⁇ 6.
  • the drug is in an oral liquid dosage form.
  • the medicament is an injectable dosage form.
  • the drug is an aqueous solution of hydrochloric acid having a pH of from 3 to 9.9 (more preferably, pH 4 to 6. 5), and the aqueous solution conforms to drinking water standards.
  • the drug is an aqueous solution of hydrochloric acid having a pH of 3.9, and the aqueous solution further contains an additional therapeutic agent for hypertension which is stable in the pH range.
  • the pH of the aqueous solution is 4 - 6 ⁇ 5 or 6. 5 - 6.
  • a preparation for treating hypertension said preparation being an aqueous solution of hydrochloric acid of pH 3 - 6.9, and said aqueous solution further comprising an additional high which is stable in said pH range Blood pressure therapeutic agent.
  • the additional therapeutic agent for hypertension is selected from, but not limited to, amlodipine, Benazepril, Captopril, clonidine (Clonidine), Enalaprilat, Felodipine, Guanazodine, Indanidine, Indapamide, Minoxidil ), Nitrendipine, Perindopril, Proroxan, Reserpiline, Triraoxamine, Triparaide, Util Utibapril, Zabiciprilat or a combination thereof PT/CN2006/000329 More preferably, the formulation is an injection.
  • the use of hydrochloric acid in the manufacture of a medicament for the treatment of a stone disease is selected from the group consisting of: kidney stones, liver stones, or gallstones.
  • the singularity of the aqueous solution of the aqueous solution is controlled to be 3-6. 9 (more preferably 4-6. 5). .
  • the aqueous solution containing hydrochloric acid can be used as edible hydrochloric acid as long as the pH of the aqueous solution is controlled at 6. 5 ⁇ 6. Drink water directly.
  • the drugs can be used in the preparation of oral solutions or injections as well as other dosage forms.
  • a therapeutic salt acid aqueous solution it is best to drink no less than 1500ml per day for consumption of hypertension or stones, and it is divided into 3 to 6 times for drinking, and 3 to 6 months for a course of treatment.
  • the recommended daily dose is 500ml, divided into two injections, intravenous drip, for 2 to 3 months for a course of treatment.
  • high blood pressure can be reduced by 1/4 after 1 year, and halved after 2 years. After three years, generally only take maintenance dose or exempt from antihypertensive drugs, and blood pressure returns to normal.
  • the above-mentioned aqueous solution containing hydrochloric acid can be continuously, stably and in large quantities by using a P H value control device.
  • the injection can be prepared by a pharmaceutically acceptable method from hydrochloric acid, as long as it is controlled to have a pH of from 3 to 6.9 (more preferably from 4 to 6. 5).
  • hydrochloric acid water from tap water, it is generally necessary to provide a purification device at the front end to meet the hygienic standard of national drinking water.
  • the hydrochloric acid of the present invention can also be applied to other solutions, such as physiological saline, dextrose solution, beverage, etc., and the method for preparing hydrochloric acid water is the same as above, as long as the pH of the oral solution or the injection is controlled. .
  • the edible hydrochloric acid water according to the present invention generally does not allow heating to be consumed, because heating causes the hydrochloric acid to volatilize and loses its therapeutic effect. Also do not drink beverages and tea that are prone to scaling, and theophylline and hydrochloric acid will neutralize and lose their effect.
  • the present invention treats 126 cases of edible salt Hypertensive patients with acid water were clinically observed, including 87 males and 39 females, with an average age of 68.2 years and an age range of 51 to 81 years.
  • the present invention has clinically observed a plurality of patients with kidney stones, liver stones and/or gallstones drinking drinking hydrochloric acid, and the results also show that drinking aqueous hydrochloric acid helps to alleviate or eliminate stones.
  • the medicine prepared by the hydrochloric acid preparation of the invention is safe and reliable for treating hypertension and calculus, has exact and obvious effects, and has obvious improvement effect on hypertension patients suffering from arteriosclerosis, and can convert calcium salts harmful to the human body into The body needs calcium.
  • the high-purity hydrochloric acid was added to a hydrochloric acid solution diluted to 2% in drinking water, and filled in a hydrochloric acid solution with a flow controller.
  • the above hydrochloric acid solution and drinking water are mixed at a certain flow ratio through a pipe, and a pH detector is disposed at the end of the pipe.
  • the hydrochloric acid aqueous solution was controlled to have a pH of 6. 5 to 6. 9.
  • Table 1 shows the improvement of hypertension in some cases after drinking the edible hydrochloric acid water of the present invention.
  • Table 1 Edible hydrochloric acid for the treatment of hypertension
  • Example 3 The high-purity hydrochloric acid was added to a hydrochloric acid solution diluted to 2% in drinking water, and filled in a hydrochloric acid solution with a flow controller. The hydrochloric acid solution and the drinking water are mixed at a certain flow ratio through a pipe, and a pH detector is disposed at the end of the pipe. The hydrochloric acid aqueous solution was controlled to have a pH of 4.0 to 6.5 to prepare edible hydrochloric acid water.
  • the patients with multiple stones were treated with the edible hydrochloric acid prepared above.
  • the patient can drink 2000ml daily, drink 500ml each morning and one hour before the Chinese food, and drink lOOOralo one hour before dinner.
  • the pH of the drinking hydrochloric acid solution is lower than 6.5, the drinking amount can be appropriately reduced.
  • the patient should drink 1000 ml per day, drink 250 ml each morning, one hour before the Chinese food, and 500 ml one hour before the evening meal.
  • Liu ⁇ 1.8 65 Drinking for one year is ⁇ 1.1, drinking for two years is 0.6 Liu ⁇ 1.1 62 drinking 1.5 years all disappear
  • a 500 ml aqueous solution of pH 6.9 in hydrochloric acid was added to a tablet of the commercially available hypertension drug indapamide (2.5 mg) to form a combination preparation containing hydrochloric acid and indapamide.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Plant Substances (AREA)

Description

盐酸在制备治疗高血压药物中的应用
(一） 技术领域
本发明涉及盐酸在制备治疗高血压和结石等疾病的药物中的应用。
(二）背景技术
人体高血压的形成， 医学界有诸多学说： 遗传学说.内分泌失调学说.饮食不 良学说等等， 但无论哪种学说， 都难以找到一种能治愈高血压的方法。 因此， 医学 界至今把人体高血压称之为 "不治之症"， 必须 "终身服药"。 目前世界上所有治 疗高血压的药物和治疗仪都是扩张动脉血管的，反复扩张动脉血管又加速动脉血管 的老化， 而且在反复扩张动脉血管的同时血管内壁上的垢会掉落下来阻塞心血管， 造成心肌梗塞等疾病。
'同时如果人类存在遗传高血压， 那么人生下来就应该是高血压， 而生下来的 人很难找到患高血压的病例；如果饮食不良造成高血压，彻底改变饮食也无济于事。 既然找不到形成高血压的确切病因， 高血压患者就不应该被定性为必须 "终生服 药"。 同时， 如果高血压是由于动脉血管老化和硬化的话， 那么仅仅用药物和治疗 仪也是难以扩张动脉血管的， 所以把高血压说成动脉管硬化、 老化也是不确切的。
(三）发明内容
本发明目的在于提供盐酸在制备治疗高血压药物中的应用。
本发明的发明人经多年的研究实践发现： 高血压的形成基于 ^下机理： 1、 水 中和食物中的碳酸氢钙分解后生成的粘结剂碳酸钙和草酸钙把人体代谢物（如胆固 醇结晶等）和进入人体的固态物粘结在动脉血管和毛细血管内壁上， 随着年龄的增 大， 动脉血管和毛细血管内壁上的垢越结越厚， 血管孔径越来越小， 从而使血流不 畅， 血压增大；
另外， 这些碳酸钙和草酸钙沉积在肾、 肝和胆等器官， 就形成了肾结石、 肝 结石和胆结石。
2、 血管内壁上的结垢使血管自身的弹性减弱， 限制了血压的自动调节。 3、 血管内壁上的长时间的结垢破坏了血管， 使其本身弹性降低。
只要把血管壁上的垢消解， 血压就恢复正常。 要消解结垢必须把粘结物碳酸 钙和草酸钙溶解， 其它被粘结的小颗粒的物质才会被分离排出体外。 发明人发现， 盐酸是最理想的溶解人体内碳酸 Φ丐和草酸钙的物质， 同时，盐酸被血管的保护膜吸 附在内壁上， 能够修复损伤的血管， 使血管重新恢复其本身的弹性。
另外， 本发明人发现， 盐酸有助于使肾结石、 肝结石和胆结石溶解， 从而缓 解或消除结石。 因此， 在本发明的第一方面， 提供了一种盐酸在制备治疗高血压药物中的应 用。
在另一优选例中， 所述水溶液的 pH控制在 3- 6. 9 (更佳地 4-6. 5)。
在另一优选例中， 所述水溶液的 pH控制在 6. 5〜6. 9。
在另一优选例中， 所述的药物为口服液剂型。
在另一优选例中， 所述的药物为注射剂剂型。
在另一优选例中， 所述的药物是 pH3-6. 9 (更佳地 pH4- 6. 5)的盐酸水溶液， 并且所述的水溶液符合饮用水标准。
在另一优选例中， 所述的药物是 pH3- 6. 9的盐酸水溶液， 并且所述的水溶 液还含有在所述 pH范围内稳定的额外的高血压治疗剂。
在本发明的第二方面， 提供了一种治疗高血压的方法， 它包括： 给予需要 治疗的对象每日平均 100-3000毫升 pH3- 6. 9的盐酸水溶液， 时间为 0. 5-6年。
更佳地水溶液的 pH为 4 - 6· 5或 6. 5-6. 9。
在本发明的第三方面， 提供了一种治疗高血压的制剂， 所述的制剂是 PH3- 6. 9的盐酸水溶液， 并且所述的水溶液还含有在所述 pH范围内稳定的额外 的高血压治疗剂。
在另一优选例中， 所述的额外的高血压治疗剂选自（但并不限于）： 氨氯地 平（Amlodipine ) 、 贝那普利（Benazepril ) 、 卡托普利（Captopril ) 、 可乐定 (Clonidine) 、 依那普利拉（Enalaprilat ) 、 非洛地平（Felodipine) 、 胍那佐 定（Guanazodine ) 、 吲达尼定（Indanidine) 、 吲达帕胺（Indapamide ) 、 米诺 地尔（Minoxidil ) 、 尼群地平（Nitrendipine) 、 培哚普利（Perindopril ) 、 普 罗克生（Proroxan) 、 利舍匹林（Reserpiline ) 、 曲莫沙明（Triraoxamine) 、 曲 帕胺（Triparaide ) 、 乌替普利（Utibapril ) 、 扎普利拉（Zabiciprilat ) 或其组 合 P T/CN2006/000329 更佳地， 所述的制剂为注射剂。
在本发明的第四方面， 提供了盐酸在制备治疗结石疾病的药物中的应用。 在另一优选例中， 所述的结石疾病选自： 肾结石、 肝结石、 或胆结石。 本发明所述盐酸用于制备治疗高血压或结石的药物时， 通常所述的药物为含 有盐酸的水溶液，所述水溶液的 pH控制在 3-6. 9 (更佳地 4-6. 5)。另据国家饮用水 标准，饮用水的 pH应该为 6. 5〜8. 5， 因而只要控制上述水溶液的 pH在 6. 5〜6. 9， 就可以将所述的含有盐酸的水溶液作为食用盐酸水直接饮用。
所述药物均可以用于制备口服液或注射剂以及其它剂型。 作为治疗作用的盐 酸水溶液在食用治疗高血压或结石时， 每日饮用最好不少于 1500ml， 分为 3〜6次 饮用， 3〜6个月为一疗程。在注射用治疗高血压时， 每日的推荐用量为 500ml， 分 两次注射， 静脉滴注， 连续 2〜3个月为一疗程。按上述用法及用量治疗高血压， 1 年后一般服药数量可减少 1/4， 2年后减半，三年后一般只服维持量或免服降压药， 血压恢复正常。
可以按如下方法人工配制口服液： 盐酸加入饮用水中搅拌均匀， 灌装灭菌前 精确检测 pH值， 将 pH值控制在 4〜6. 9； 食用盐酸水的 pH控制在 6. 5〜6. 9。
工业法配制时， 可以采用 PH值控制装置来进行连续、 稳定、 大批量地制备上 述含有盐酸的水溶液。
可以由盐酸按药学上通常的方法制备注射剂，只要控制注射剂 PH在 3-6. 9 (更 佳地 4- 6. 5)即可。 采用自来水制造盐酸水时， 一般应该在前端设置净化装置使其达到国家饮用 水的卫生标准。
为了达到治疗高血压的目的， 本发明所述的盐酸也可以应用于其它溶液中， 如生理盐水、葡萄糖溶液、饮料等， 其配制盐酸水的方法同上， 只要控制口服液或 注射剂的 pH即可。 本发明所述的食用盐酸水一般不允许加热饮用， 因为加热会使盐酸挥发而失 去疗效。 也不要饮容易结垢的饮料和茶水， 茶碱和盐酸会中和失去作用。
为说明本发明所述的盐酸对高血压的治疗效果， 本发明对 126例饮用食用盐 酸水的高血压患者进行了临床观察， 其中男 87例， 女 39例， 平均年龄 68. 2岁， 年龄范围 51〜81岁。
使用结果表明： 食用盐酸水配合降压药治疗高血压患者和完全饮用食用盐酸 水治疗高血压患者已痊愈的 89例， 食用盐酸水配合降压药治疗高血压患者， 服用 的降压药己减量血压完全控制在正常范围的 30例。 服降压药控制不到正常范围的 高血压患者，饮用食用盐酸水 2年后，服同样的药和药量能控制到正常范围的高血 压患者 7例。
另外， 本发明对饮用食用盐酸水的多例肾结石、 肝结石和 /或胆结石患者进 行了临床观察， 结果同样表明， 饮用盐酸水溶液有助于缓解或消除结石。
本发明所述的盐酸制备制得的药物治疗高血压和结石安全可靠， 有着确切、 明显的效果，对动脉血管硬化的高血压患者也有明显的改善作用，并可以使危害人 体的钙盐转化为人体需要的钙。
(四）具体实施方式
下面结合具体实施例， 进一步阐述本发明。 应理解， 这些实施例仅用于说明 本发明而不用于限制本发明的范围。下列实施例中未注明具体条件的实验方法，通 常按照常规条件，或按照制造厂商所建议的条件。除非另外说明，份数和百分比是 重量份数和重量百分比。 实施例 1
将高纯度稀盐酸加入饮用水中搅拌均匀，精确控制 pH值为 6. 5〜7,可直接服 用。 实施例 2
将高纯度盐酸加入饮用水中稀释至 2%的盐酸溶液，灌装于带有流量控制器的 盐酸溶液中。将上述盐酸溶液和饮用水以一定流量比经管道混合，所述管道末端设 置 pH值检测器。 控制盐酸水溶液 pH在 6. 5〜6. 9， 制得食用盐酸水。
采用上述制得食用盐酸水对 16例髙血压患者进行治疗观察， 患者每日饮用 2000ml , 早、 中餐前一小时各饮 500ml， 晚餐前一小时饮 1000ml。
表 1为饮用本发明所述食用盐酸水后部分病例的高血压病情改善情况。 表 1 食用盐酸水治疗高血压
Figure imgf000006_0001
由表 1可以看出， 盐酸水溶液用于治疗高血压疗效明显， 总有效率 100 %。 实施例 3 将高纯度盐酸加入饮用水中稀释至 2%的盐酸溶液，灌装于带有流量控制器的 盐酸溶液中。将上述盐酸溶液和饮用水以一定流量比经管道混合，所述管道末端设 置 pH值检测器。 控制盐酸水溶液 pH在 4.0〜6.5， 制得食用盐酸水。
采用上述制得食用盐酸水对多例结石患者进行治疗观察。 按 PH6.5 的盐酸水 溶液计算， 患者每日饮用 2000ml， 早、 中餐前一小时各饮 500ml， 晚餐前一小时饮 lOOOralo 如果饮用的盐酸水溶液的 pH低于 6.5， 则饮用量可适当降低。 例如对于 饮用 pH5.0的水溶液时， 患者每日饮用 1000ml， 早、 中餐前一小时各饮 250ml， 晚 餐前一小时饮 500ml。
治疗结果如表 2和 3所示。 表 2食用盐酸水治疗肾结石
Figure imgf000007_0001
表 3 食用盐酸水治疗肝胆结石
姓名 肝、胆结石 (cm) 年龄 结石的治疗效果
覃某 0.7X0.6 63 饮用 10个月 B超检查痊愈
应某 0.7 53 饮用一年为 0.4， 1.5年消失
徐某 0.8 74 饮用 2年消失
张某 1.6 69 饮用 1年为 1.2; 2年为 0.6; 2.5年消失 Φ1.5 2颗
陆某 75 饮用 1年为 2颗 0.7， 2.5年全部消失
Φ0.8 1颗
陈某 Φ1.3 52 饮用一年 B超为 0.8
刘某 Φ1.8 65 饮用一年为 Φ 1.1， 饮用二年为 0.6 刘某 Φ1.1 62 饮用 1.5年全部消失
倪某 Φ1.9X5 55 饮用 1年为 Φ1.6Χ4.1， 饮用 2年为 1.6X3.1 祝某 Φ2.1 67 饮用 1.5年为 Φ1.1 由表 2和 3可以看出， 盐酸水溶液对应于肾结石、 肝结石和胆结石， 有较明 显的疗效。 实施例 4
盐酸水溶液 +高血压药物的复方制剂
在 500ml pH6.9 的盐酸水溶液中， 加入一片市售的高血压药物吲达帕胺 (2.5mg) 片剂， 构成含有盐酸和吲达帕胺的复方制剂。
用类似方式， 可以制得盐酸 +额外高血压药物的复方制剂。 在本发明提及的所有文献都在本申请中引用作为参考， 就如同每一篇文献 被单独引用作为参考那样。此外应理解，在阅读了本发明的上述讲授内容之后， 本领域技术人员可以对本发明作各种改动或修改， 这些等价形式同样落于本申 请所附权利要求书所限定的范围。

Claims

权 利 要 求
1、 盐酸在制备治疗高血压药物中的应用。
2、 如权利要求 1 所述的盐酸在制备治疗高血压药物中的应用， 其特征在 于所述的药物为含有盐酸的水溶液， 所述水溶液的 PH控制在 3-6. 9。
3、 如权利要求 2所述的盐酸在制备治疗高血压药物中的应用， 其特征在 于所述水溶液的 pH控制在 6. 5〜6. 9。
4、 如权利要求 2或 3所述盐酸在制备治疗高血压药物中的应用， 其特征 在于所述的药物为口服液剂型。
5、 如权利要求 2所述的盐酸在制备治疗高血压药物中的应用， 其特征在 于所述的药物为注射剂剂型。
6、如权利要求 1所述的用途， 其特征在于， 所述的药物是 PH3-6. 9的盐酸 水溶液， 并且所述的水溶液还含有在所述 pH范围内稳定的高血压治疗剂。
7、—种治疗高血压的方法， 其特征在于， 给予需要治疗的对象每日平均 100-300毫升 pH3- 6. 9的盐酸水溶液， 时间为 0. 5-6年。
8、—种治疗高血压的制剂， 其特征在于， 所述的制剂是 pH3- 6. 9的盐酸水 溶液， 并且所述的水溶液还含有在所述 pH范围内稳定的高血压治疗剂， 所述 的治疗剂选自： 氨氯地平（Amlodipine) 、 贝那普利（Benazepril ) 、 卡托普利 (Captopril ) 、 可乐定（Clonidine ) 、 依那普利拉（Enalaprilat ) 、 非洛地平 (Felodipine ) 、 胍那佐定（Guanazodine ) 、 吲达尼定（Indanidine ) 、 吲达帕 胺（Indapamide ) 、 米诺地尔（Minoxidil ) 、 尼群地平（Nitrendipine ) 、 培哚 普利（Perindopril ) 、 普罗克生（Proroxan) 、 利舍匹林（Reserpiline) 、 曲莫 沙明（Triraoxamine ) 、 曲帕胺（Tripamide ) 、 乌替普利（Utibapril ) 、 扎普利 拉（Zabiciprilat ) 或其组合。
9、 盐酸在制备治疗结石疾病的药物中的应用。
10、 如权利要求 9所述的应用， 其特征在于， 所述的结石疾病选自： 肾结 石、 肝结石、 或胆结石。
PCT/CN2006/000329 2005-03-10 2006-03-06 Utilisation d’acide chlorhydrique pour la fabrication d’un medicament pour le traitement de l'hypertension WO2006094451A1 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
EA200701936A EA012616B1 (ru) 2005-03-10 2006-03-06 Применение соляной кислоты для изготовления лекарственного средства для лечения повышенного давления
MX2007010918A MX2007010918A (es) 2005-03-10 2006-03-06 El uso del acido clorhidrico para la elaboracion de un medicamento para el tratamiento de la hipertension.
AU2006222417A AU2006222417A1 (en) 2005-03-10 2006-03-06 The use of hydrochloric acid for the manufacture of a medicament for the treatment of hypertension
US11/908,053 US20080317871A1 (en) 2005-03-10 2006-03-06 Use of Hydrochloric Acid For the Manufacture of a Medicament For the Treatment of Hypertension
JP2008500030A JP2008532952A (ja) 2005-03-10 2006-03-06 高血圧治療のための薬剤の製造における塩酸の適用
EP06705725A EP1864671A4 (en) 2005-03-10 2006-03-06 USE OF HYDROCHLORIC ACID FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF HYPERTENSION
BRPI0608022-7A BRPI0608022A2 (pt) 2005-03-10 2006-03-06 processo para fabricação de um medicamento para tratar hipertensão, formulação anti-hipertensão e processo para fabricação de um medicamento para tratar cálculo

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN200510049329.8 2005-03-10
CNA2005100493298A CN1830454A (zh) 2005-03-10 2005-03-10 盐酸在制备治疗高血压药物中的应用

Publications (1)

Publication Number Publication Date
WO2006094451A1 true WO2006094451A1 (fr) 2006-09-14

Family

ID=36952948

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2006/000329 WO2006094451A1 (fr) 2005-03-10 2006-03-06 Utilisation d’acide chlorhydrique pour la fabrication d’un medicament pour le traitement de l'hypertension

Country Status (10)

Country Link
US (1) US20080317871A1 (zh)
EP (1) EP1864671A4 (zh)
JP (1) JP2008532952A (zh)
KR (1) KR20070116087A (zh)
CN (1) CN1830454A (zh)
AU (1) AU2006222417A1 (zh)
BR (1) BRPI0608022A2 (zh)
EA (1) EA012616B1 (zh)
MX (1) MX2007010918A (zh)
WO (1) WO2006094451A1 (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101234123A (zh) * 2008-02-02 2008-08-06 王德寿 一定浓度的盐酸水在治疗血管疾病中的应用
WO2010009589A1 (zh) * 2008-07-21 2010-01-28 Liu Zhiren 盐酸在制备治疗胃炎、肠炎和脉管炎药物中的应用
CN105902565A (zh) * 2016-05-11 2016-08-31 吴健忠 一种逆转动脉及其他软组织硬化的方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1301545A (zh) * 1999-12-27 2001-07-04 王德山 一种复方降血压药
US20030178030A1 (en) * 2002-03-20 2003-09-25 Constantz Brent R. Methods and devices for the in situ dissolution of renal calculi

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6300361B1 (en) * 1990-07-25 2001-10-09 Novartis Ag Stabilized pharmaceutical compositions comprising acid donors
US20040115134A1 (en) * 1999-06-22 2004-06-17 Elan Pharma International Ltd. Novel nifedipine compositions
JP2002255801A (ja) * 2000-12-26 2002-09-11 Mitsukan Group Honsha:Kk 高血圧予防用組成物
US7141251B2 (en) * 2001-04-06 2006-11-28 Cytorex Biosciences, Inc. Pharmacologically active strong acid solutions
EG24716A (en) * 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1301545A (zh) * 1999-12-27 2001-07-04 王德山 一种复方降血压药
US20030178030A1 (en) * 2002-03-20 2003-09-25 Constantz Brent R. Methods and devices for the in situ dissolution of renal calculi

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FAN Y.: "The determination of free chlorine in food additive hydrochloride acid", CHINA CHLOR-ALKALI, no. 2, February 2003 (2003-02-01), pages 34 - 36, XP008120850 *
See also references of EP1864671A4 *

Also Published As

Publication number Publication date
KR20070116087A (ko) 2007-12-06
EP1864671A1 (en) 2007-12-12
EA200701936A1 (ru) 2008-02-28
BRPI0608022A2 (pt) 2009-11-03
JP2008532952A (ja) 2008-08-21
EA012616B1 (ru) 2009-10-30
AU2006222417A1 (en) 2006-09-14
CN1830454A (zh) 2006-09-13
MX2007010918A (es) 2008-03-13
US20080317871A1 (en) 2008-12-25
EP1864671A4 (en) 2010-01-20

Similar Documents

Publication Publication Date Title
RU2454996C2 (ru) Применение ксантогумола и изоксантогумола в качестве активного вещества для профилактики и/или борьбы с заболеваниями печени
CN105263579B (zh) 左西替利嗪和孟鲁司特在治疗血管炎中的用途
RU2668882C2 (ru) Жидкая фармацевтическая композиция
JP2013541583A (ja) 組み合わせ組成物
WO2006094451A1 (fr) Utilisation d’acide chlorhydrique pour la fabrication d’un medicament pour le traitement de l'hypertension
JP2024026871A (ja) 慢性便秘症を治療するための医薬組成物
Offerhaus Drugs for the elderly
US11864570B2 (en) Therapeutic composition including carbonated solution
WO2009094811A1 (fr) Préparation d'un mélange acide de gelée royale et son application
HO et al. Massive Amikacin" Overdose"
WO2009100591A1 (zh) 一定浓度的盐酸水在治疗血管疾病中的应用
GB2435418A (en) Composition for preventing and alleviating alcohol hangover
JP6184960B2 (ja) メラトニンの新規用途
US20220160619A1 (en) Effervescent Drug Formulations
WO2008043243A1 (fr) Utilisation d'acide chlorhydrique dans la fabrication de médicament destiné au traitement de maladie entraînée par...
RU2177320C1 (ru) Средство, ослабляющее выраженность постинтоксикационного алкогольного синдрома
JP2004538239A (ja) 肝線維症および肝硬変の処置および予防のための薬剤組成物
CN115768414A (zh) 氨苯砜制剂及其使用方法
JP2007520560A (ja) 疼痛性障害の処置のための方法および組成物
Canty et al. Postoperative pain therapy
JP2010159216A (ja) 鎮痛剤及び鎮痛システム
CN106552225A (zh) 一种快速化解结石的药物配方
US7718191B2 (en) Pharmaceutical product which is used to reduced or stop moderate or severe snoring
Sloan et al. Selected Therapeutic Problems
CN102366620A (zh) 治疗癫痫病的中药制剂

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2008500030

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/010918

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 11908053

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006222417

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2006705725

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: RU

WWE Wipo information: entry into national phase

Ref document number: 1200702070

Country of ref document: VN

Ref document number: 1020077023137

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: RU

WWE Wipo information: entry into national phase

Ref document number: 200701936

Country of ref document: EA

ENP Entry into the national phase

Ref document number: 2006222417

Country of ref document: AU

Date of ref document: 20060306

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2006222417

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2006705725

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0608022

Country of ref document: BR

Kind code of ref document: A2